A Randomized, Double-Blind, Double-Dummy, Parallel Fluconazole Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis (RVVC)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oteseconazole (Primary) ; Fluconazole
Indications Vulvovaginal candidiasis
Focus Registrational; Therapeutic Use
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

03 Nov 2021 According to a Mycovia Pharmaceuticals media release, The first subject was enrolled in September 2021, and enrollment is expected to complete in Q3 2022.
13 Oct 2021 New trial record
29 Sep 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last Verified September 2021).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight